Annovis Bio’s buntanetap shows efficacy in Phase 3 Parkinson’s study

Annovis Bio announced new data from its Phase III PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson’s disease. Key findings from the study include: buntanetap stops cognitive decline in all enrolled patients and improves cognition in patients with mild dementia; all treatment groups maintained baseline levels, indicating a statistically significant effect of the drug in stopping cognitive decline. Buntanetap improves motor and non-motor PD-related functions in patients with a diagnosis of over 3 years. In patients diagnosed with PD for longer than 3 years, buntanetap significantly improved scores vs. placebo and baseline. Buntanetap improves motor and non-motor PD-related functions in patients with Postural Instability and Gait Difficulty. Buntanetap maintained a consistent safety profile across all participants, with no significant differences between early and advanced PD patients confirming our previous AD data.